The Company anticipates sharing initial results from the study in March 2025. These results will inform Silexion's development strategy for SIL-204.

Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Part of a series to inform nuclear facility designers, vendors, operators and State governments about IAEA safeguards and how associated requirements can be considered early in the design phase of a ...

Alpha Modus Holdings, Inc. engages in creating, developing, and licensing data driven technologies to enhance consumers in-store digital experience at the point of decision in the United States.

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...